{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=2",
    "query": {
      "intervention": "IFN",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T18:42:01.011Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00069511",
      "title": "12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "UT-231B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2003-07",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 6,
      "location_summary": "Gainesville, Florida • New Orleans, Louisiana • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069511"
    },
    {
      "nct_id": "NCT01156311",
      "title": "BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 108,
      "start_date": "2010-06",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-21",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156311"
    },
    {
      "nct_id": "NCT02568787",
      "title": "The Effect of an RBAC Supplement (BRM4) on NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "rice bran arabinoxylan compound (RBAC)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2016-05",
      "completion_date": "2017-06-10",
      "has_results": false,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02568787"
    },
    {
      "nct_id": "NCT00006384",
      "title": "SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "semaxanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2011-10-20",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006384"
    },
    {
      "nct_id": "NCT00206648",
      "title": "An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Betaferon/Betaseron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 271,
      "start_date": "2003-03",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2014-12-31",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 51,
      "location_summary": "Tucson, Arizona • Berkeley, California • Irvine, California + 46 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206648"
    },
    {
      "nct_id": "NCT00250796",
      "title": "Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Thalidomide, alpha interferon",
          "type": "DRUG"
        },
        {
          "name": "Thalidomide, interferon, Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2000-09",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2010-01-07",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 2,
      "location_summary": "Albuquerque, New Mexico • Santa Fe, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00250796"
    },
    {
      "nct_id": "NCT02370329",
      "title": "P1101 in Treating Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Ropeginterferon Alfa-2B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-08-12",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370329"
    },
    {
      "nct_id": "NCT01147042",
      "title": "Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "IFN-Gamma Therapy",
        "CGD Gene Mutation",
        "CGD Response to IFNg",
        "CGD - Chronic Granulomatous Disease",
        "Immunodeficiency Disease"
      ],
      "interventions": [
        {
          "name": "IFN-gamma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2010-05-18",
      "completion_date": "2014-11-14",
      "has_results": true,
      "last_update_posted_date": "2017-09-20",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147042"
    },
    {
      "nct_id": "NCT00085670",
      "title": "Cytokine Gene Polymorphisms in Bone Marrow Failure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bone Marrow Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "2 Years to 80 Years"
      },
      "enrollment_count": 79,
      "start_date": "2005-02-11",
      "completion_date": "2007-03-14",
      "has_results": false,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085670"
    },
    {
      "nct_id": "NCT00056862",
      "title": "Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2003-03",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2013-12-06",
      "last_synced_at": "2026-09-18T18:42:01.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056862"
    }
  ]
}